|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
7.230 USD |
-1.77% | +1.54% | +76.34% | |
Published on 06/20/2025 at 16:53
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Exagen Registers 1.15 Million Share Sale by Investor Perceptive Credit Holdings |
04:53pm |
MT |
|
Exagen Prices $17.6 Million Public Offering; Shares Down |
May. 08 |
MT |
|
Exagen Inc. Prices Public Offering Of Common Stock At $5.25 Per Share |
May. 08 |
RE |
|
Exagen Inc., Q1 2025 Earnings Call, May 05, 2025 |
May. 05 |
|
|
Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 05 |
CI |
|
Exagen Inc. Provides Earnings Guidance for Full Year 2025 |
May. 05 |
CI |
|
Exagen Enters up to $75 Million Credit Facility |
Apr. 28 |
MT |
|
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors |
Apr. 28 |
CI |
|
Exagen posts smaller-than-expected fourth-quarter net loss |
Mar. 11 |
RE |
|
Exagen Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
Mar. 11 |
CI |
|
Exagen Inc., Q4 2024 Earnings Call, Mar 11, 2025 |
Mar. 11 |
|
|
Exagen Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
Mar. 11 |
CI |
|
Exagen Inc. Provides Earnings Guidance for First Quarter of 2025 |
Mar. 11 |
CI |
|
Exagen Inc. Secures Conditional Ny State Approval for New Lupus and Rheumatoid Arthritis Biomarkers |
Jan. 12 |
CI |
|
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform |
Nov. 14 |
CI |
|
Exagen Inc., Q3 2024 Earnings Call, Nov 12, 2024 |
Nov. 12 |
|
|
Earnings Flash (XGN) EXAGEN Reports Q3 Revenue $12.5M |
Nov. 12 |
MT |
|
Exagen Inc. Provides Earnings Guidance for the Full Year 2024 |
Nov. 12 |
CI |
|
Exagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 12 |
CI |
|
Exagen Inc., Q2 2024 Earnings Call, Aug 05, 2024 |
24-08-05 |
|
|
Earnings Flash (XGN) EXAGEN Posts Q2 Revenue $15.1M, vs. Street Est of $13.1M |
24-08-05 |
MT |
|
Exagen Inc. Revises Earnings Guidance for the Full Year 2024 |
24-08-05 |
CI |
|
Exagen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 |
24-08-05 |
CI |
|
Exagen Inc. Announces Chief Financial Officer Changes |
24-08-01 |
CI |
|
Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating |
24-05-14 |
MT |
XGN: Dynamic Chart
Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
More about the company
Buy
Average target price
7.750USD
Spread / Average Target
+5.30%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
